DIGITAL NEWSROOM

Featured post

May 27, 2022

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022

Read more »

Featured post

May 19, 2022

Exact Sciences at DDW 2022

Exact Sciences at DDW 2022

Read more »

Featured post

May 11, 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX® GPS™ Test, for the First Time in Localized Prostate Cancer Patients

Read more »

May 27, 2022

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022
May 19, 2022

Exact Sciences at DDW 2022
May 11, 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients
April 28, 2022

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
March 07, 2022

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer
January 19, 2022

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients
January 09, 2022

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results
January 09, 2022

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
January 09, 2022

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients
December 09, 2021

Exact Sciences Commits $500,000 to Urban League Black Business Hub
December 08, 2021

New Data Presented at SABCS^® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making
December 01, 2021

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test

Choose your country or region:

DIGITAL NEWSROOM

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Exact Sciences Commits $500,000 to Urban League Black Business Hub

New Data Presented at SABCS^® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test

Multimedia

Quick Links

Choose your country or region:

DIGITAL NEWSROOM

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX® GPS™ Test, for the First Time in Localized Prostate Cancer Patients

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX® GPS™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Exact Sciences Commits $500,000 to Urban League Black Business Hub

New Data Presented at SABCS® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test

Multimedia

Quick Links

Follow us on

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

New Data Presented at SABCS^® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test